Literature DB >> 23040598

Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged ≥ 70 years.

Kai M Eggers1, Per Venge, Lars Lind.   

Abstract

The levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) are closely related to cardiac abnormalities and adverse outcomes in the general population. However, little is known about the course of NT-proBNP levels over time, the underlying conditions, and the prognostic effect of changes. To investigate these issues, we measured the NT-proBNP levels (Elecsys 2010, Roche Diagnostics) in community-dwellers participating in the Prospective Investigation of the Vasculature in Uppsala Seniors study at 70 (n = 1,005) and 75 (n = 817) years of age. The total follow-up was 8.0 years. In subjects with available results from both examinations, the median NT-proBNP levels increased from 106 pg/ml (25th to 75th percentile 62 to 174) to 125 pg/ml (25th to 75th percentile 73-234; p <0.001). The change in NT-proBNP levels was positively and independently related to male gender, baseline information on ischemic electrocardiographic changes, renal dysfunction, impaired left ventricular ejection fraction, and intercurrent cardiovascular events (e.g., myocardial infarction, stroke, or coronary revascularization). The change in NT-proBNP levels independently predicted mortality after the measurements at 75 years of age (all-cause mortality, adjusted hazard ratio 2.4, 95% confidence interval 1.6 to 3.6; cardiovascular mortality, adjusted hazard ratio 2.3, 95% confidence interval 1.2 to 4.5). Compared to those without significant NT-proBNP changes (n = 606), subjects with increasing levels (n = 162) had markedly increased all-cause mortality (adjusted hazard ratio 4.3, 95% confidence interval 2.1 to 8.8). No subject with decreasing NT-proBNP levels (n = 49) died. In conclusion, repeat measurements of NT-proBNP might add useful information to the routine clinical assessment in subjects aged ≥ 70 years, because changes in their levels were associated with cardiovascular risk indicators and strongly predictive of mortality.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040598     DOI: 10.1016/j.amjcard.2012.08.058

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis.

Authors:  Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

2.  Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs
Journal:  Diabetes Metab       Date:  2015-06-03       Impact factor: 6.041

3.  The differential diagnostic value of serum NT-proBNP in hospitalized patients of heart failure with pneumonia.

Authors:  Shuangshuang Yang; Linbin Li; Ju Cao; Hongsong Yu; Huajian Xu
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

4.  Level and Change in N-Terminal Pro-B-Type Natriuretic Peptide and Kidney Function and Survival to Age 90.

Authors:  Astrid D Häberle; Mary L Biggs; Mary Cushman; Bruce M Psaty; Anne B Newman; Michael G Shlipak; John Gottdiener; Chenkai Wu; Julius M Gardin; Nisha Bansal; Michelle C Odden
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-02-25       Impact factor: 6.053

5.  Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study.

Authors:  Petra G van Peet; Anton J M de Craen; Jacobijn Gussekloo; Wouter de Ruijter
Journal:  Age (Dordr)       Date:  2014-05-08

6.  Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Lori B Daniels; Paul Clopton; Christopher R deFilippi; Otto A Sanchez; Hossein Bahrami; Joao A C Lima; Russell P Tracy; David Siscovick; Alain G Bertoni; Philip Greenland; Mary Cushman; Alan S Maisel; Michael H Criqui
Journal:  Am Heart J       Date:  2015-09-28       Impact factor: 4.749

7.  Change in NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Level and Risk of Dementia in Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mohammad R Ostovaneh; Kasra Moazzami; Kihei Yoneyama; Bharath A Venkatesh; Susan R Heckbert; Colin O Wu; Steven Shea; Wendy S Post; Annette L Fitzpatrick; Gregory L Burke; Hossein Bahrami; Otto A Sanchez; Lori B Daniels; Erin D Michos; David A Bluemke; João A C Lima
Journal:  Hypertension       Date:  2019-12-23       Impact factor: 10.190

8.  Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Nisha Bansal; Leila R Zelnick; Elsayed Z Soliman; Amanda Anderson; Robert Christenson; Christopher DeFilippi; Rajat Deo; Harold I Feldman; Jiang He; Bonnie Ky; John Kusek; James Lash; Stephen Seliger; Tariq Shafi; Myles Wolf; Alan S Go; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2020-12-09       Impact factor: 11.072

9.  N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease.

Authors:  José Tuñón; Javier Higueras; Nieves Tarín; Carmen Cristóbal; Óscar Lorenzo; Luis Blanco-Colio; José Luis Martín-Ventura; Ana Huelmos; Joaquín Alonso; Álvaro Aceña; Ana Pello; Rocío Carda; Dolores Asensio; Ignacio Mahíllo-Fernández; Lorenzo López Bescós; Jesús Egido; Jerónimo Farré
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

10.  Heart failure in elderly: progress in clinical evaluation and therapeutic approach.

Authors:  Massimo Iacoviello; Valeria Antoncecchi
Journal:  J Geriatr Cardiol       Date:  2013-06       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.